Stock ALCJ CROSSJECT
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Crossject

Equities

ALCJ

FR0011716265

Real-time Euronext Paris
Other stock markets
 05:19:32 2024-05-09 EDT 		5-day change 1st Jan Change
2.13 EUR -1.39% Intraday chart for Crossject +7.58% -57.14%
05-03 Crossject: praised for extended agreement on Zepizure CF
05-02 Crossject Signs A Geographic Extension of ZEPIZURE Commercialization Agreement in Europe CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Crossject: praised for extended agreement on Zepizure
CF
Crossject Signs A Geographic Extension of ZEPIZURE Commercialization Agreement in Europe
CI
CROSSJECT : Patience is a virtue… hopefully
AL
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023
CI
CROSSJECT : Invest Securities slightly reduces its target
CF
CROSSJECT : Securing the financing needs
AL
Crossject: share price falls after convertible bond issue
CF
CROSSJECT : No news is not always good news...
AL
Crossject: strategy advances, but visibility worries
CF
CROSSJECT : Marketing initiative in the US
AL
French Pharmaceutical Crossject Taps Syneos Health for US Commercialization of Epilepsy Rescue Treatment
MT
CROSSJECT : A new distribution agreement in Northern Europe
AL
Crossject: commercial agreement in Northern Europe
CF
Crossject Signs ZENEO(R) Commercialization Agreement for Northern Europe
CI
Crossject Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Crossject Completes European, US Audits for Manufacturing of Seizure Medication for US
MT
AFT Pharmaceuticals Secures Australia, New Zealand License for Epilepsy Rescue Medication
MT
Crossject Société Anonyme Signs New Licensing Agreement on Zeno Midazolam Epilepsy Rescue Therapy with AFT Pharmaceuticals for Australia & New Zealand
CI
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Crossject to Release Positive Headline Results of Its Clinical Study with Zeneo® Midazolam
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALCJ Stock
  4. News Crossject
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW